The genetic evolution of treatment-resistant cutaneous, acral, and uveal melanomas

Alvin P. Makohon-Moore, Evan J. Lipson, Jody E. Hooper, Amanda Zucker, Jungeui Hong, Craig M. Bielski, Akimasa Hayashi, Collin Tokheim, Priscilla Baez, Rajya Kappagantula, Zachary Kohutek, Vladimir Makarov, Nadeem Riaz, Michael A. Postow, Paul B. Chapman, Rachel Karchin, Nicholas D. Socci, David B. Solit, Timothy A. Chan, Barry S. TaylorSuzanne L. Topalian, Christine A. Iacobuzio-Donahue

Research output: Contribution to journalArticlepeer-review


Purpose: Melanoma is a biologically heterogeneous disease composed of distinct clinicopathologic subtypes that frequently resist treatment. To explore the evolution of treatment resistance and metastasis, we used a combination of temporal and multilesional tumor sampling in conjunction with whole-exome sequencing of 110 tumors collected from 7 patients with cutaneous (n ¼ 3), uveal (n ¼ 2), and acral (n ¼ 2) melanoma subtypes. Experimental Design: Primary tumors, metastases collected longitudinally, and autopsy tissues were interrogated. All but 1 patient died because of melanoma progression. Results: For each patient, we generated phylogenies and quantified the extent of genetic diversity among tumors, specifically among putative somatic alterations affecting therapeutic resistance. Conclusions: In 4 patients who received immunotherapy, we found 1-3 putative acquired and intrinsic resistance mechanisms coexisting in the same patient, including mechanisms that were shared by all tumors within each patient, suggesting that future therapies directed at overcoming intrinsic resistance mechanisms may be broadly effective.

Original languageEnglish (US)
Pages (from-to)1516-1525
Number of pages10
JournalClinical Cancer Research
Issue number5
StatePublished - Mar 1 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'The genetic evolution of treatment-resistant cutaneous, acral, and uveal melanomas'. Together they form a unique fingerprint.

Cite this